Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea
By Katherine Hamilton
Mineralys Therapeutics said its drug lorundrostat didn't meaningfully reduce sleep apnea in a Phase 2 trial.
The biopharmaceutical company said Monday that the treatment didn't demonstrate a reduction in the Apnea-Hypopnea Index, which measures the number of times breathing stops or becomes shallow during an hour of sleep.
Shares fell 3%, to $26.35, in after-hours trading.
Lorundrostat did show meaningful reductions in blood pressure and had a meaningful safety profile, Chief Executive Jon Congleton said.
The trial involved 48 patients and lasted four weeks.
The Radnor, Pa., company also said the Food and Drug Administration accepted the new drug application for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.
The FDA has assigned a Prescription Drug User Fee Act target action date of Dec. 22.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 09, 2026 19:29 ET (23:29 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
What’s Ahead for Stocks This Quarter—and Where to Invest
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States